Why Xenon Pharmaceuticals stock crashed 31% even after filing azetukalner FDA application
Xenon Pharmaceuticals shares suffered their biggest recent sell-off after the company paused new enrollment in late-stage depression studies over neuropsychiatric adverse events, overshadowing an important FDA filing for azetukalner in focal seizures.